Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWH7NQ)

Drug Name

Alprostadil Drug Info

Synonyms

Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil

Indication

Disease Entry	ICD 11	Status	REF
Aorta coarctation		Approved	[1]
Diabetic foot ulcer	BD54	Approved	[2]
Erectile dysfunction	HA01.1	Approved	[3]
Pulmonary hypertension	BB01	Approved	[1]
Tetralogy of fallot		Approved	[1]

Therapeutic Class

Vasodilator Agents

Cross-matching ID

PubChem CID: 5280723
ChEBI ID: CHEBI:15544
CAS Number: CAS 745-65-3
TTD Drug ID: DMWH7NQ
VARIDT Drug ID: DR00210
INTEDE Drug ID: DR1923
ACDINA Drug ID: D00828

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[17]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[18]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[19]
Omidenepag isopropyl	DMUX7Z8	Glaucoma/ocular hypertension	9C61	Approved	[20]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[21]
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[22]
CP-533536	DMZEJLB	Osteoporosis	FB83.0	Phase 2	[23]
Taprenepag	DM1TSHL	Glaucoma/ocular hypertension	9C61	Phase 2	[24]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
PF-4418948	DMMETU8	Endometriosis	GA10	Phase 1	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Thromboxane A2 receptor (TBXA2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ridogrel	DMWH9CN	Acute myocardial infarction	BA41	Approved	[26]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[21]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[27]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[28]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[29]
TAK-128	DMHPEFS	Diabetic neuropathy	8C0Z	Phase 2	[30]
Ifetroban sodium	DMZP84Y	Thrombosis	DB61-GB90	Phase 2	[31]
Ifetroban	DMEV39E	Aspirin-induced asthma	CA23.20	Phase 2	[32]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[33]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[34]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Multidrug resistance-associated protein 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[35]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[36]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[37]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[7]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[38]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[40]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[41]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[42]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Organic anion transporter 1 (SLC22A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[43]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[44]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[45]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[46]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[46]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[46]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[47]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[48]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[49]
FLUORESCEIN	DMQTFAO	Ocular disease	1F00.1Z	Approved	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Organic anion transporting polypeptide 2A1 (SLCO2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[51]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[5]
Latanoprost	DMI5OXG	Ocular hypertension	9C61.01	Approved	[52]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[5]
------------------------------------------------------------------------------------

Drug(s) Transported By Organic anion transporting polypeptide 3A1 (SLCO3A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[6]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[51]
Benzylpenicillin	DMS9503	Actinomycosis		Phase 3	[51]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[6]
------------------------------------------------------------------------------------

Drug(s) Affected By Prostaglandin D2 receptor (PTGDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[54]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[55]
------------------------------------------------------------------------------------

Drug(s) Affected By Renin (REN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[56]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[57]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[58]
Reboxetine	DM26PRD	Depression	6A70-6A7Z	Approved	[59]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[60]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[61]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[62]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[63]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[64]
Chlorthalidone	DM4DMBT	Edema	MG29	Approved	[65]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Angiotensinogen (AGT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[66]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Reboxetine	DM26PRD	Depression	6A70-6A7Z	Approved	[59]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[69]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[70]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[62]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[71]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[72]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[73]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Natriuretic peptides A (NPPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[74]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[75]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[76]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Cilazapril	DM4V6JA	Congestive heart failure	BD10	Approved	[78]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[72]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[79]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[81]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[82]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[83]
Terbutaline	DMD4381	Asthma	CA23	Approved	[84]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[85]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[86]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[87]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[90]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[91]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Natriuretic peptides B (NPPB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[75]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[87]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[92]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[93]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[94]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[95]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[97]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[98]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Vasopressin V1a receptor (AVPR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[99]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[100]
Vasopressin	DMQ2FPC	Diabetes insipidus	5A61.5	Approved	[101]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[102]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[103]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[104]
Insulin	DMB7CE0	Diabetic complication	5A2Y	Approved	[16]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[16]
Dinoprost Tromethamine	DMXQKSL	Abortion	JA00	Approved	[16]
Bardoxolone methyl	DMODA2X	Mixed connective tissue disease	4A43.3	Phase 3	[105]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin E2 receptor EP2 (PTGER2)	TT1ZAVI	PE2R2_HUMAN	Agonist	[2]
Thromboxane A2 receptor (TBXA2R)	TT2O84V	TA2R_HUMAN	Modulator	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 2A1 (SLCO2A1)	DT021JD	SO2A1_HUMAN	Substrate	[5]
Organic anion transporting polypeptide 3A1 (SLCO3A1)	DTVNRXW	SO3A1_HUMAN	Substrate	[6]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[7]
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Prostaglandin dehydrogenase 1 (HPGD)^{Main DME}	DEHKSC6	PGDH_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[10]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Post-Translational Modifications	[11]
Natriuretic peptides A (NPPA)	OTMQNTNX	ANF_HUMAN	Gene/Protein Processing	[12]
Natriuretic peptides B (NPPB)	OTSN2IPY	ANFB_HUMAN	Gene/Protein Processing	[13]
Prostaglandin D2 receptor (PTGDR)	OT92UR1A	PD2R_HUMAN	Protein Interaction/Cellular Processes	[14]
Renin (REN)	OT52GZR2	RENI_HUMAN	Gene/Protein Processing	[10]
Vasodilator-stimulated phosphoprotein	OTFC3010	VASP_HUMAN	Post-Translational Modifications	[15]
Vasopressin V1a receptor (AVPR1A)	OTKR8AFL	V1AR_HUMAN	Drug Response	[16]

------------------------------------------------------------------------------------

References

1	Alprostadil FDA Label
2	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1882).
4	Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
5	Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
6	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
7	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
8	Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7.
9	Effect of calcium ionophore A23187 on prostaglandin synthase type 2 and 15-hydroxy-prostaglandin dehydrogenase expression in human chorion trophoblast cells. Am J Obstet Gynecol. 2008 Nov;199(5):554.e1-8.
10	Catecholamine and renin-angiotensin response during controlled hypotension induced by prostaglandin E1 combined with hemodilution during isoflurane anesthesia. J Clin Anesth. 1997 Jun;9(4):321-7. doi: 10.1016/s0952-8180(97)00011-1.
11	Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol. 2004 Jan;65(1):196-206. doi: 10.1124/mol.65.1.196.
12	Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Jpn Heart J. 1999 May;40(3):321-34. doi: 10.1536/jhj.40.321.
13	Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail. 2005 Dec;7(7):1156-63. doi: 10.1016/j.ejheart.2005.05.001. Epub 2005 Aug 5.
14	Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.
15	Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade. Transl Res. 2010 Feb;155(2):97-108. doi: 10.1016/j.trsl.2009.08.005. Epub 2009 Sep 15.
16	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
17	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
18	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
19	Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
20	Clinical pipeline report, company report or official report of Santen Pharmaceutical.
21	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
22	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
23	Pfizer. Product Development Pipeline. March 31 2009.
24	A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
25	Clinical pipeline report, company report or official report of Tempest Therapeutics.
26	Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
27	Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
28	Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
29	Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
30	ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
31	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
32	Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
33	In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
34	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
35	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
36	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
37	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
38	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
39	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
40	P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
41	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
42	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
43	The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
44	Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
45	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
46	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
47	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
48	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
49	Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
50	Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
51	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
52	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
53	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
54	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
55	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
56	Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
57	Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
58	Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
59	Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
60	Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
61	Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
62	Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
63	beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
64	Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
65	Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
66	Genistein disrupts glucocorticoid receptor signaling in human uterine endometrial Ishikawa cells. Environ Health Perspect. 2015 Jan;123(1):80-7. doi: 10.1289/ehp.1408437. Epub 2014 Aug 19.
67	Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids. Toxicology. 2017 Apr 15;381:51-63.
68	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
69	Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther. 1980 Apr;27(4):533-43. doi: 10.1038/clpt.1980.75.
70	Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008 Jun;26(6):1147-55. doi: 10.1097/HJH.0b013e3282f97dde.
71	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
72	Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J. 1993 Jun;69(6):512-5. doi: 10.1136/hrt.69.6.512.
73	Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999 Mar;33(3):850-5. doi: 10.1161/01.hyp.33.3.850.
74	Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):45-8. doi: 10.1007/BF03190404.
75	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
76	Opioid peptides attenuate blood pressure increase in acute respiratory failure. Peptides. 2001 Apr;22(4):631-7. doi: 10.1016/s0196-9781(01)00373-4.
77	Atrial-like Engineered Heart Tissue: An In?Vitro Model of the Human Atrium. Stem Cell Reports. 2018 Dec 11;11(6):1378-1390. doi: 10.1016/j.stemcr.2018.10.008. Epub 2018 Nov 8.
78	Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens. 1992 Nov;5(11):837-46. doi: 10.1093/ajh/5.11.837.
79	Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Press. 2002;11(2):91-4. doi: 10.1080/08037050211263.
80	1,25-dihydroxyvitamin D inhibits human ANP gene promoter activity. Regul Pept. 2005 Jun 30;128(3):197-202. doi: 10.1016/j.regpep.2004.12.030.
81	Experimental studies on cortisol-induced hypertension in humans. J Hum Hypertens. 1995 Jun;9(6):395-9.
82	Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
83	Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
84	Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
85	beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
86	Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
87	Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
88	Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
89	Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
90	Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
91	Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
92	Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ J. 2009 Oct;73(10):1965-8. doi: 10.1253/circj.cj-08-0181. Epub 2009 Jan 27.
93	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
94	Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
95	Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation. 2004 Sep 28;110(13):1787-93. doi: 10.1161/01.CIR.0000143072.36782.51. Epub 2004 Sep 13.
96	Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
97	Docetaxel induced cardiotoxicity. Heart. 2001 Aug;86(2):219. doi: 10.1136/heart.86.2.219.
98	Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
99	Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
100	Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
101	Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
102	Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
103	Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
104	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
105	Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017 Oct;363(1):114-125.